Antonio Arrieta, M.D. is board certified in Pediatric Infectious Diseases. Dr. Arrieta is the PSF Chief of the Division of Infectious Diseases and a Clinical Professor at UC Irvine.
Dr. Arrieta specializes in the treatment of serious community acquired and nosocomial infections and has added expertise in HIV medicine. He completed his fellowship at UCI-Memorial/Miller Children’s Hospital in Long Beach. He did his residency at Southern Illinois University in Springfield.
Dr. Arrieta is a graduate of Universidad Peruana Cayetano Heredia in Lima, Peru and speaks fluent Spanish. He was voted as one of Orange County’s Top Doctors for 2009 & 2010.
Academic Appointments
Clinical Professor, Pediatrics, University of California, Irvine, College of Medicine
Director Pediatric Infectious Diseases, CHOC, Orange, CA, 2004 – present
Director of Infectious Diseases Clinical Research, CHOC, Orange, CA, 2004 – present
Medical Director, KIDS Clinic (Pediatric HIV Center), 1991 – present
Principal Investigator, PACTG protocols (Sub Site of UCLA Main PACTG Site)
Research Projects
A Multicentre, Double- Blind, Comparative, Randomised Study to Evaluate the Efficacy and Safety of Micafungin (FK463) versus Liposomal Amphotericin B (AmBisome ®) in the Treatment of Invasive Candidiasis and Candidaemia Protocol FG-463-21-08. July 2003-July 2006. Principal Investigator: Antonio Arrieta, MD. (Fujisawa Healthcare Inc.)
A Pivotal Phase 3 Study of MEDI-524 (Numax), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High Risk Children. Protocol #: MI-CP110. August 2004-October 2006. Principal investigator: Gary Goodman, MD; Co-investigator: Antonio Arrieta, MD (MedImmune)
A prospective, open label, non –randomized, naturalistic, long term safety surveillance, observational study of ciprofloxacin (either as oral suspension, oral tablets, or sequential IV oral therapy or purely IV therapy) in the treatment of pediatric patients with a variety of infectious diagnoses. Pediatric quinolone use in pediatrics (QUIP) STUDY. Protocol 100201. October 2000- 2009. Principal Investigator: Antonio Arrieta, MD. (Bayer)- closed to enrollment- follow up only
Investigator Initiated Safety and Efficacy of Liposomal Amphotericin B (LAM-B) for the Prevention of Invasive Candidiasis in Preterm Infants. November 2003- September 2008. Principal Investigator: Antonio Arrieta, MD (Fujisawa Healthcare Inc– closed to enrollment
IRB #050805 and IRB#070751 (Season 1 and Season 2)- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease MI-CP-124. August 2005-October 2008. Principal Investigator: Gary Goodman, Co-investigator: Antonio Arrieta, MD (MedImmune)
A Prospective, Non-Interventional Study to Evaluate the Incidence of Hospitalizations and Medically-Attended Lower Respiratory Tract Infection (MALRI) in Premature Infants 32 to 35 Weeks Gestational Age Who Are Not Recommended to Receive Prophylaxis for RSV (MI-MA 140). October 2006- September 2007. Principal Investigator: Gary Goodman, MD; Co-investigator: Antonio Arrieta, MD (MedImmune)
Screening of Mannose-Binding Lectin (MBL) Status in Pediatric Hematology/Oncology Patients. Protocol EZN-2232-03-S. June 2007-July 2009. Principal Investigator: Antonio Arrieta, MD (Enzon Pharmaceuticals)
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients with Fever and Neutropenia. Protocol EZN-2232-03. June 2007-July 2009. Principal Investigator: Antonio Arrieta, MD (Enzon Pharmaceuticals)
A Phase I, Open-Label Study of the Safety and Tolerability of Repeated-Dose Micafungin as Antifungal Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplant Protocol 9463-CL-2103. May 2007-July 2009. Principal Investigator: Antonio Arrieta, MD (Astellas Pharma US).
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate a
Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency, Monoclonal Antibody to Respiratory Syncytial Virus (RSV) for the Treatment of Children Hospitalized with RSV illness. (MI-CP-141). July 2007- November 2008. Principal Investigator: Antonio Arrieta, MD (MedImmune)
A Phase 3, Randomized, Double-Blind, Multicenter Study to Compare the Efficacy and Safety of Micafungin versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis (PROTOCOL 04-0-199/ISN 9463-CL-2303)- June 2006-closed to enrollment. Principal Investigator: Antonio Arrieta, MD (Astellas)
Expanded Access Protocol for VariZig. June 2006-present Principal Investigator: Jasjit Singh, MD; Sub investigator: Antonio Arrieta, MD (Astellas) (Cangene/FFF)
IRB Studies
IRB#060640- Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) L1 Virus Like Particle (VLP) Vaccine (GARDASIL ®) in HIV infected Children > 7 to < 12 years of age. Protocol PACTG 1047. June 2006-closed to enrollment, patients in follow up. Principal Investigator: Antonio Arrieta, MD (PACTG)
IRB # 0611107- A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu ®) for the Treatment of Children less than 24 months of age with Confirmed Influenza infection (CASG 114, DMID 06-0059). November 2006-2011. Principal Investigator: Negar Ashouri, MD; Sub investigator: Antonio Arrieta, MD (CASG-DMID)
IRB# 070211 – A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin (FK463) in Infants and Toddlers (> 4 months to < 24 months of age) with Esophageal Candidiasis or Other Invasive Candidiasis. Protocol 9463-CL-2102. February 2007-2011. Principal Investigator: Antonio Arrieta, MD (Astellas Pharma US)
IRB#1010111 Emergency Use Protocol for CMX001 in a Bone Marrow Transplant Patient with AdV, BKV, and CMB disseminated Infections. October 2010-2011. Principal Investigator: Antonio Arrieta, MD (Chimerix)
IRB # 1012127 Emergency Use Protocol for CMX001 in a Bone Marrow Transplant Patient with AdV, and CMB disseminated Infections. December 2010-2011. Principal Investigator: Antonio Arrieta, MD (Chimerix)
CURRENT STUDIES – PEDIATRIC INFECTIOUS DISEASES CLINICAL RESEARCH (Ongoing Clinical Trials)
IRB# 070329- A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin (FK463) in Children (2-5 Years and 6-11 Years) and Adolescents (12-16 Years) with Esophageal Candidiasis or Other Invasive Candidiasis. Protocol 9463-CL-2101- March 2007-present. Principal Investigator: Antonio Arrieta, MD (Astellas Pharma US)
IRB# 080101- Phase 1B Study of the Safety, Tolerance and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia. Protocol P03579. January 2008-present. Principal Investigator: Antonio Arrieta, MD. (Schering-Plough).
IRB#80892 – International Fungal Network. August 2008-present. (International Fungal Network Coordinating Center)
IRB # 0809106- A Prospective, Open Label Study to Assess the Pharmacokinetics, Safety & Efficacy of Anidulafungin When Used to Treat Children with Invasive Candidiasis, Including Candidemia (Protocol A8851008). September 2008-present. Principal Investigator: Antonio Arrieta, MD (Pfizer)
IRB # 0810113- An Evaluation of the Safety, Efficacy, and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged Seven to Seventeen Years with Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens (DAP-PEDS-07-03). October 2008-present. Principal Investigator: Antonio Arrieta, MD (Cubist)
IRB#90542 – An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic Safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the Treatment of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected children 2-
IRB#911113 An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Three Months to Twenty-Four months Who are concurrently receiving standard antibiotic therapy for proven or Suspected Gram-positive infection. (Cubist Pharmaceuticals)
IRB #100211 An open label, prospective pharmacokinetic/pharmacodynamic and safety evaluation of intravenous oseltamivir (Tamiflu) in the treatment of infants less than one year of age with influenza infection. February 2010-present. (F. Hoffman-LaRoche LTD)
IRB # 100216 A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 year Old Adolescent Patients. March 2010-present. (Trius Therapeutics)
IRB#100432 Safety and Efficacy of Micafungin for the Treatment and Prevention of Fungal Infections in Neonatal and Pediatric Patients at CHOC. April 2010-present. (Astellas)
IRB#100435 Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients. (Bayer Healthcare)
IRB#100664 A Randomized, Double Blind Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, oral) Moxifloxacin Versus Comparator in Pediatric Subjects with Complicated Intra-Abdominal Infection. July 2010-present. (Bayer Healthcare)
IRB#100771T Serum and Stool Calprotectin and Serum Lypopolysaccharide Binding Protein as Markers of Serious Infection and Necrotizing Enterocolitis in Premature Infants. August 2010-present. (PSF Tithe Committee)
IRB #110113 Prospective Surveillance to evaluate the Impact of the introduction of PREVNAR 13 on Streptococcus Pneumoniae invasive infections in Orange County, California. February 2011-present. (Pfizer)
IRB #110335 A Randomized, Placebo-controlled, Multi-Site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation. April 2011-present. (Chimerix Inc.)
IRB #110337 Safety and Pharmacokinetics of Metronidazole in Premature Infants. April 2011-present. (Duke Clinical Research Institute)
IRB #110663 Treatment and Management of empyema at CHOC from 2000-2011. July 2011. (CHOC)
IRB#111088 Phase 3 SDIV ibuprofen vs. acetaminophen for fever reduction in children 0-16 years. (Cumberland Pharmaceuticals)
Publications
1. Ashouri N, Checchia PA, Arrieta AC. Kawasaki Disease. Pediatric Hospital Medicine, Second Edition 2008. pp 397-402
2. Arrieta A, Acute Rheumatic Fever . Pediatric Hospital Medicine, Second Edition. 2008 pp 412-415
3. Armenian SH, Singh J, Arrieta AC. Risk Factors for mortality resulting from blood stream infections in a pediatric intensive care unit. Pediatr Infect Dis J. 2005 Apr; 24 (4): 309-14.
4. Singh J, Arrieta AC. Management of Meningococcemia: an updated review. Indian J Pediatr. 2004 Oct; 71 (10): 909-13.
5. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, Cohan D, Nilson B, Petru A, Ruiz J, Weintrub PS, Wenman W, Maldonado YA; California Pediatric HIV Study Group. Temporal trends in early clinical manifestations of perinatal HIV infection in a population based cohort. JAMA. 2005 May 11; 293-(18) 2221-31.
6. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DP, Walsh TJ. Safety, Tolerability and Pharmacokinetics of Micafungin (FK-463) in Febrile Neutropenic Patients. Antimicrobial Agents Chemother. 2005. Aug; 49 (8): 3317-24.
7. Arrieta A. Treatment of Invasive Fungal Infections in the Pediatric Patient with Echinocandin therapy. Submitted and accepted for publication- Infectious Diseases Express Report
8. Anaisse EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, et al. Clinical Research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis. 2006 Oct 15;43 (8): 1031-9.
9. Hope WW, Seibel NK, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ. Buell DN, Gumbo T, Drusano GL, Walsh TJ. Population Pharmacokinetics of Micafungin in Pediatric Patients and the Implications for Antifungal Dosing. Antimicrob Agents Chemother. 2007 Jul;51:3714-9.
10. Yellin AE, Johnson J, Higareda I, Congeni BL, Arriet AC, Fernsler D, West J, Gesser R. Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg. 2007 Sep; 194 (3):367-74.
11. Ashouri N, Singh J, Arriet A. Micafungin in Pediatrics: when one size does not fit all. Expert Opin. on Drug Metab. & Toxicol. 2008 April; 4 (4): 463-469
12. Bendig E, Singh J, Butler TJ, and Arriet AC. The Impact of the Central Venous Catheter on the Diagnosis of Infective Endocarditis Using Duke Criteria in Children with Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2008;27:636-639
13. Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll A, and Arriet A. for the Micafungin Invasive Candidiasis Study Group. Micafungin vs Liposomal Amphotericin B for Pediatric Patients with Invasive Candidiasis: A Randomized Double-Blind trial. Pediatr Infect Dis J. 2008 Sep;27(9):820-6
14. Suesaowalak M, Cheung MM, Tucker D, Chang AC, Arriet A. Chlamydophila pneumoniae Myopericarditis in a Child. Pediatr Cardiol. 2009 Apr;30(3):336-9.
15. Smith PB, Walsh TJ, Hope W, Arriet A, Takada A, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, Benjamin DK jr. Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. Pediatr Infect Dis J. 2009 May;28(5):412-5.
16. Benjamin DK, Smith PB, Arriet A, Castro L, Sanchez PJ, Kaufman D, Arnold L, Kovanda L, Sawamoto T, Buell D, Hope W, Walsh TJ. Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. Clinical Pharmacology & Therapeutics 2010;87 (1) 93-99.
17. Antonio C Arrieta MD, Kathy Shea BA, Vijay Dhar MD, John Cleary MD, Sudeep Kukreja MD, Mindy Morris RNP, Ofelia Vargas-Shiraishi MS, Negar Ashouri MD, Jasjit Singh MD. Once Weekly Liposomal Amphotericin B as Candida Prophylaxis In Very Low Birth Weight Premature Infants; A Prospective, Randomized, Open-Label, Placebo-Controlled Pilot Study. Clinical Therapeutics 2010:32 (2) 265-271
18. Chuang M, Singh J, Ashouri N, Katz M, Arriet A. Listeria Meningitis after Influximab Therapy for Ulcerative Colitis. Journal of Pediaric GI and Nutrition 2010 Mar;50(3): 337-9.
19. Hope WW. Smith PB, Arriet A, Buell DN, Roy M, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother.2010 Jun;54(6):2633-7
20. Walsh Tj, Drisctoll T, Milligan PA, Wood, Arriet A. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23.
21. Arrieta A, Singh J, Ashouri N, Vargas-Shiraishi O. Streptococcus pneumonie bloodstream infection in hospitalized children after implementation of pneumococcal conjugate vaccine. J Pediatr Infect Dis 2011; 6(2)
22. Green J, Singh J, Cheung M, Adler F, Ashouri N, Arriet A. A cluster of pediatric endemic typhus cases in Orange County, California: Case reports and literature review. Pediatr Infect Dis J. 2011 Feb:30(2):163-5
23. Benjamin D, Arriet A, Smith, Brian, Cohen-Wolkowiez M, Castro L. et al. Population Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants with Suspected or Complicated Intra-abdominal Infections. Pediatric Infectious Disease Journal (in press). 2011 Oct
24. Arriet A, Maddison P, Groll, A. Safety of Micafungin in Pediatric Clinical Trials. Pediatr Infect Dis J. 2011 Jun;30(6):e97-e102.
25. Nieves D, Arriet A, Singh J, Adler F, Ashouri N, McGuire T. Clinical and Laboratory Features of Pertussis in Infants at the Onset of a California Epidemic. J. Pediatr 2011, September 16.
26. Driscoll T, Yu L, Haydar F, Krance R, Nemecek E, Blumer J, Arriet A, et al. Pharmacokinetics and safety of intravenous voriconazole to oral switch in immunocompromised children compared to adults. Antimicrob. Agents Chemother. 2011 0: AAC.00531-11
27. Freire A, Arriet A, Stevenson P, Undre N. Pharmacolinetics of Micafungin in Pediatric Patients with Invasive Candidiasis and Candidemia. Submitted to The Pediatric Infectious Disease Journal. August 2011.
Presentations
1. Nieves D, Singh J, Lang D, McGuire T, Dhar V, and Arrieta, A. Etiology and Outcome of Nosocomial Blood Stream Infections (N-SBI) in very low birth weight neonates (VLBW-N). Poster presentation. Pediatric Academic Society. May 14-17 2005. Washington DC
2. Bendig E, Singh J, Butler T and Arrieta A C Cardiac Complications in Pediatric Patients with Staphylococcus aureus(SA) Bacteremia(SAB): A Retrospective Review Utilizing the Duke’s Criteria(Dk-C). Poster Presentation. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 3-5, 2006. Basel, Switzerland
3. Bendig E, Arrieta A C, Butler T and Singh J, Venous Access Devices (VAD) as a Risk for Infective Endocarditis (IE) in Pediatric Staphylococcus aureus Bacteremia (SAB). Poster Presentation. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 3-5, 2006. Basel, Switzerland
4. Bendig E, Singh J, Butler T and Arrieta A C Resurgence of Staphylococcus aureus (SA) Bacteremia (SAB) in Children: Exploring the Changes in Epidemiology, Management and Outcome. Poster Presentation. 106th General Meeting of the American Society for Microbiology, May 21-25, 2006 Orlando, Florida
5. Cerny LM, McGuire T, Singh J and Arrieta A C- Incidence of Serious Bacterial Infections (SBI) in Infants < 60 days old with Respiratory Syncytial Virus (RSV) infection. Usefulness of the “Rochester Criteria (RC). Poster presentation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA
6. Arrieta A C, Seibel N, Kovanda L, Keirns J, Facklam D, Buell D, and Walsh TJ. Safety, Efficacy and Pharmacokinetics (PK) of Micafungin (mica) in Pediatric (ped) Patients (pts). Poster presentation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA
7. Walsh TJ , Driscoll TA, Groll AH , Arrieta AC, Klein N, Bradley J, Jafri HS, Schlamm HT, Wood N , Milligan P, Lutsar I. Pediatric Voriconazole Study Group. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Hospitalized Children. Poster presentation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA
8. Late breaker Abstract Safety and Efficacy of Micafungin vs AmBisome in Candida Infections in Pediatric Patients. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA
9. Arrieta A, Queiroz-Telles F, Berezin E, Leverger G, Freire A, Diekmann-Berndt H, Koblinger for the Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B (AmBisome®) in paediatric patients with invasive candidiasis or candidaemia. ECCMID Mycamine Symposium , April 2007. Munich
10. Arrieta A, Maddison, P, Groll AH. Micafungin in Pediatric Patients: Assessment of Safety in Clinical Trials. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL.
11. Singh J, Bendig EA, Vargas-Shiraishi OM, Wronski, SA, Ashouri N, Arrieta, AC Microbiology (Micro) of Community Acquired (CA) Blood Stream Infection (BSI) After Introduction of Streptococcus pneumoniae (SP) Conjugated vaccine and its impact on the reliability of traditional diagnostic criteria. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL.
12. Walsh TJ, Driscoll TA, Groll AH, Arrieta AC, Klein N, Bradley J, Jafri HS, Laws J, Schlamm HT, Troke PF, Wood N, Milligan P, Lutsar I . Population Pharmacokinetic (POP-PK) Analysis of Voriconazole (VRC): Developing a Rationale for Dosage in Pediatric Patients. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL.
13. Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Ashouri N, Singh J: Safety of Liposomal Amphotericin as a Once Weekly Antifungal Prophylactic Regimen in Very Low Birth Weight Premature Infants. Poster Presentation at ECCMID, Barcelona, Spain, April 2008.
14. Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Morris M, Ashouri N, Singh J: Safety and Efficacy of Liposomal Amphotericin B (L-AmB) as a Prophylactic Regimen for the Prevention of Candida Colonization and Systemic Infection in Very Low Birth Weight (VLBW) Premature Infants. Poster presentation at PAS, Honolulu, HI, May 2008.
15. Arrieta A, Maddison P, Groll AH. Micafungin in Pediatric Patients: Assessment of Safety in Clinical trials. Poster presentation at PAS, Honolulu, HI, May 2008
16. Freire A, Arrieta A, Undre N. Pharmacokinetics of Micafungin in Pediatric Patients with Invasive Candidiasis and Candidemia. Poster presentation at PAS, Honolulu, HI, May 2008
17. D.K.. Benjamin Jr , P.B. Smith, A. Arrieta, L. Castro, P. Sanchez, D. Kaufman, L. Arnold, L. Kovanda, T. Sawamoto, D.N. Buell, W.W. Hope, T.J. Walsh. Safety and Pharmacokinetics (PK) of Repeat-Dose Micafungin (MICA) in Neonates. Poster Presentation at ICAAC May 2008
18. AC Arrieta, N. Seibel, L. Kovanda, J. Keirns, D. Facklam, D. Buell, TJ Walsh. Safety, Efficacy and Pharmacokinetics of Micafungin in Pediatric Patients. Poster presentation at the European Academy of Pediatrics congress in Nice, France, October 2008.
19. Benjamin DK, Smith PB, Arrieta A, Castro L, Sanchez PJ, Kaufman D, et al. Safety and Pharmacokinetics of Repeat-Dose Micafungin in Neonates and Young Infants. Poster presentation at the 2009 Pediatric Academic Society (PAS) meeting.
20. Arrieta A, Seibel N, Walsh TJ, Arnold L, Groll AH. Micafungin for the Treatment of Pediatric Invasive Fungal Infections. Poster presentation at the International Symposium on Intensive Care and Emergency Medicine (ISICEM), Brussels, Belgium, March 24-27, 2009.
21. Arrieta A, Seibel N, Walsh TJ, Arnold L, Groll AH. Micafungin: Overview of Efficacy in Children. Poster presentation at the 2009 European Society for Paediatric Infectious Diseases (ESPID) meeting.
22. Arrieta AC, Maddison P, Groll AH. Micafungin: Overview of Safety in Children. Poster presentation at the 2009 European Society for Paediatric Infectious Diseases (ESPID) meeting. Brussels, Belgium, June 09-13, 2009
23. Arrieta AC, Vargas-Shiraishi O, Ashouri N, Adler F, Singh J. Streptococcus Pneumoiae Blood Stream Infections (BSI) in Hospitalized Children after Broad Utilization of Heptavalente Pneumococcal Conjugate Vaccine (PCV-7). Poster presentation at the 2009 European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009.
24. Ashouri N, Singh J, Vargas-Shiraishi O, Arrieta A. Clinical and Microbiological Factors Affecting Outcome in Hospitalized Children with Candidemia. Poster presentation at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009
25. Ashouri N, Singh J, Vargas-Shiraishi O, Arrieta A. Identification of Factors Affecting Incidence and Outcome of Candidemia in a Neonatal Intensive Care Unit for Developing Prophylaxis Strategies. Poster presentation at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009
26. R. Avery, F.M. Marty, L. Strasfeld, I. Lee, A. Arrieta, S. Chou, S. Villano. Oral Maribavir (MBV) for Treatment of Resistant or Refractory Cytomegalovirus (CMV) Infections in Transplant Recipients. Oral Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).San Francisco, California, September 12-15, 2009.
27. Ashouri N. Arrieta AC, Vargas-Shiraishi O, Adler F, Singh J. Staphylococcus aureus (S aureus) Bacteremia in Hospitalized Infants Less Than Three Months of Age. Poster presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2009, San Francisco, CA
28. Arrieta, AC, Vargas-Sharaishi O, Singh J, Ashouri N, Kukreja S, Dhar V. Impact of intra-abdominal pathology in late onset blood stream infections in neonatal intensive care patients. Poster presentation to the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases, Nice, France, May 4-8, 2010
29. Smith PB, Apparelli EV, Castro LM, Valencia G, Bidegain M, A Arrieta, Benjamin DK, et al. Pharmacokinetics and Safety of Meropenem in Young Infants with Intra-Abdominal Infections. Poster presentation at the 2010 Pediatric Academic Society (PAS) annual meeting, Vancouver, Canada. May 1-4.
30. Singh J, Ashouri N, Nieves, D, Mcguire T, Arrieta A. Clinical and Laboratory Features of Pertussis During a California Epidemic. Poster presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, September 12-15, 2010
31. Hoy Z, Singh J, Vargas-Sharaishi O, Arrieta A. Central line associated blood stream infections in pediatric patients with short bowel syndrome. Poster presentation to the American Society for Microbiology. New Orleans, May 2011.
32. Fisher J, Singh J, Ashouri N. Arrieta A.C., Adler F, Nieves D. Outcome of late onset neonatal sepsis due to bacteremic urinary tract infections. Accepted to present at the 7th World Congress of the World Society for Pediatric Infectious Diseases. Melbourne, Australia. November 2011
Publications
Publications† link:
Dr. Antonio Arrieta Publications
( † Disclaimer: This search is powered by Google Scholar. Google Scholar is a third-party website with no affiliation with CHOC.)